Pluristem Therapeutics (PSTI) Stock Price, News & Analysis

Company Overview

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.00 to $1.58
• 52-Week Range: N/A
• Volume: 2,128 shs
• Average Volume: 715,259 shs
• Market Capitalization: $32.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PSTI Stock Analysis - Frequently Asked Questions

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics Inc. (NASDAQ:PSTI) posted its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.05.

When did Pluristem Therapeutics' stock split?

Shares of Pluristem Therapeutics reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Pluristem Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pluristem Therapeutics investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Meta Platforms (META), Gilead Sciences (GILD), Novavax (NVAX) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 11/14/2024
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PSTI
• CUSIP: N/A
• CIK: 1158780
• Web: www.pluristem.com
• Phone: 972747107171
• Fax: 972-74-710-8787
• Employees: 153
• Year Founded: 2003

Profitability

• EPS (Most Recent Fiscal Year): ($1.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-49,870,000.00
• Net Margins: N/A
• Pretax Margin: -20,024.79%
• Return on Equity: -100.63%
• Return on Assets: -55.46%

Debt

• Debt-to-Equity Ratio: 0.57
• Current Ratio: 8.22
• Quick Ratio: 8.22

Sales & Book Value

• Annual Sales: $20,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.80 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 32,348,000
• Free Float: 30,601,000
• Market Cap: $32.35 million
• Optionable: Optionable
• Beta: 1.91